









Markets
/
Stocks
/
nasdaq-btai
/

BioXcel Therapeutics Inc

BTAI

1.500USD

+0.130+9.49%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

29.99MMarket Cap

LossP/E TTM



BioXcel Therapeutics Inc

1.500

+0.130+9.49%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of BioXcel Therapeutics Inc

Currency: USD Updated: 2026-02-05

Key Insights

BioXcel Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 124 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.60.In the medium term, the stock price is expected to trend down.The company has shown very weak stock market performance over the past month, in line with its fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

BioXcel Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

124 / 159

Overall Ranking

431 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

BioXcel Therapeutics Inc Highlights

StrengthsRisks

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 504.27% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.27M.

Overvalued

The company’s latest PE is -0.00, at a high 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 292.75K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.27.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

14.600

Target Price

+824.05%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-05

The current financial score of BioXcel Therapeutics Inc is 5.71, ranking 152 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 98.00K, representing a year-over-year decrease of 54.21%, while its net profit experienced a year-over-year decrease of 126.45%.

Score

Industry at a Glance

Previous score

5.71

Change



Financials

6.14

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.12

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.36

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

BioXcel Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-05

The current valuation score of BioXcel Therapeutics Inc is 5.84, ranking 138 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -0.00, which is -15.79% below the recent high of -0.00 and -2365363.16% above the recent low of -89.89.

Score

Industry at a Glance

Previous score

5.84

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 124/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-05

The current earnings forecast score of BioXcel Therapeutics Inc is 7.20, ranking 111 out of 159 in the Pharmaceuticals industry. The average price target is 12.00, with a high of 38.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

7.20

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

14.600

Target Price

+965.69%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

BioXcel Therapeutics Inc

BTAI

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-05

The current price momentum score of BioXcel Therapeutics Inc is 1.45, ranking 156 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.85 and the support level at 1.13, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.43

Change

0.02

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.070

Sell

RSI(14)

36.741

Neutral

STOCH(KDJ)(9,3,3)

20.111

Neutral

ATR(14)

0.122

Low Volatility

CCI(14)

-97.304

Neutral

Williams %R

80.556

Oversold

TRIX(12,20)

-0.729

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.502

Sell

MA10

1.594

Sell

MA20

1.756

Sell

MA50

1.837

Sell

MA100

2.068

Sell

MA200

2.272

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-05

The current institutional shareholding score of BioXcel Therapeutics Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 5.25%, representing a quarter-over-quarter decrease of 11.55%. The largest institutional shareholder is The Vanguard, holding a total of 292.75K shares, representing 1.34% of shares outstanding, with 288.79% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Millennium Management LLC

1.03M

Bioxcel Corp

480.34K

-0.00%

Mehta (Vimal)

382.43K

+0.10%

The Vanguard Group, Inc.

Star Investors

192.13K

+920.64%

Armistice Capital LLC

288.13K

-7.75%

Oaktree Capital Management, L.P.

Star Investors

284.10K

Fidelity Management & Research Company LLC

198.60K

Geode Capital Management, L.L.C.

125.24K

+344.40%

XTX Markets LLC

113.36K

+383.97%

Risk Assessment

Currency: USD Updated: 2026-02-05

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of BioXcel Therapeutics Inc is 2.43, ranking 127 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.20. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.